BTG : Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients

10 April 2008 : BTG (LSE: BGC), the life sciences company, reports additional details from its positive clinical proof of concept study of BGC20-0166 in subjects with mild to severe obstructive sleep apnoea.BGC20-0166 is a novel combination of two marketed serotonin modulating drugs being developed for the treatment of obstructive sleep apnoea syndrome (OSA). OSA is a sleep-related breathing disorder that affects more than 12 million adults in the US, according to the National Institutes of Health, making OSA as common as adult diabetes. BGC20-0166 has the potential to significantly advance the management of OSA as there are currently no approved drug therapies to treat this disorder... BTG's Press Release -